Sanj K. Patel - 10 Apr 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHAIRMAN & CEO, Director
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 10 Apr 2023
Net transactions value: -$31,412
Form type: 4
Filing time: 11 Apr 2023, 17:05:23 UTC
Previous filing: 03 Apr 2023
Next filing: 06 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+9,992	+28%		45,507	10 Apr 2023	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$31,412	-2,933	-6.4%	$10.71	42,574	10 Apr 2023	Direct
holding	KNSA	Class A Common Share						83,336	10 Apr 2023	Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013
holding	KNSA	Class A Common Share						109,795	10 Apr 2023	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	+9,992	+50%	$0.000000	29,975	10 Apr 2023	Class A Common Share	9,992		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.